Vivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric
January 27, 2022 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Announces 18X Increase in Sleep Apnea Diagnostic Testing By Vivos Dentists Using SleepImage Technology
January 19, 2022 07:30 ET
|
Vivos Therapeutics, Inc
Vivos Also Announces Improved Pricing Agreement With SleepImage Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test HIGHLANDS RANCH, Colo., Jan. 19, 2022 ...
Vivos Therapeutics’ mmRNA Oral Appliance Now Eligible for Medicare Reimbursement
December 14, 2021 07:30 ET
|
Vivos Therapeutics, Inc
mmRNA is the first and only appliance of its kind covered by Medicare Part of the Vivos System treatment, the mmRNA appliance represents a highly effective, non-surgical, non-invasive, and...
Vivos Therapeutics Announces Registration with Health Canada to Manufacture and Sell Sleep Disorder, Snoring and Sleep Apnea Appliances to Canadian Dentists
December 09, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics to Participate at the Benzinga Global Small Cap Conference
December 03, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Reports Third Quarter 2021 Financial Results and Operational Update
November 15, 2021 16:05 ET
|
Vivos Therapeutics, Inc
Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and...
Vivos Therapeutics to Participate at the Q4 Virtual Investor Summit
November 15, 2021 07:00 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative...
Vivos Therapeutics Schedules Third Quarter 2021 Financial Results Conference Call
November 09, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics to Participate at the Benzinga Global Small Cap Conference
October 22, 2021 07:30 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Announces 2021 Annual Breathing Wellness Conference Presented by The Vivos Institute
October 19, 2021 16:00 ET
|
Vivos Therapeutics, Inc
HIGHLANDS RANCH, Colo., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing...